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ABSTRACT  
 
In this paper we report the analysis of seven benzopyridoindole and benzopyridoquinoxaline drugs 
binding to different duplex DNA and triple helical DNA, using an approach combining electrospray 
ionization mass spectrometry (ESI-MS), tandem mass spectrometry (MS/MS), and molecular 
modeling. The ligands were ranked according to the collision energy (CE50) necessary to dissociate 
50% of the complex with the duplex or the triplex in tandem MS. To determine the probable ligand 
binding site and binding mode, molecular modeling was used to calculate relative ligand binding 
energies in different binding sites and binding modes. For duplex DNA binding, the ligand-DNA 
interaction energies are roughly correlated with the experimental CE50, with the two benzopyridoindole 
ligands more tightly bound than the benzopyridoquinoxaline ligands. There is however no marked AT 
vs. GC base preference in binding, as supported both by the ESI-MS and the calculated ligand binding 
energies. Product ion spectra of the complexes with triplex DNA show only loss of neutral ligand for 
the benzopyridoquinoxalines, and loss of the third strand for the benzopyridoindoles, the ligand 
remaining on the duplex part. This indicates a higher binding energy of the benzopyridoindoles, and 
also shows that the ligands interact with the triplex via the duplex. The ranking of the ligand interaction 
energies compared with the CE50 values obtained by MS/MS on the complexes with the triplex clearly 
indicates that the ligands intercalate via the minor groove of the Watson-Crick duplex. Regarding 
triplex vs. duplex selectivity, our experiments have demonstrated that the most selective drugs for 
triplex share the same heteroaromatic core. 
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INTRODUCTION 
DNA-binding reagents exhibit a high potential as chemotherapeutic drugs, and many approved 
anticancer therapies include molecules that are DNA binders. These agents interfere with gene 
replication or transcription in proliferating cells like cancer cells [1]. However, classical 
chemotherapies are still very toxic for healthy cells as well, and cause many unwanted effects. One of 
the most challenging goals is therefore the design of molecules which bind to nucleic acids with high 
structural and sequence selectivity in order to target specific disease-related genes. Triplex DNA 
formation is one such strategy to target specific DNA sequences [2-6]. Triple helices of 
polyribonucleotides were first observed in 1957 [7]. DNA triplexes are formed when a DNA strand 
called the antigene binds to a duplex (the gene) in its major groove. Combining triplex-specific ligands 
with antigenes is therefore a means of targeting genes more specifically than with duplex-binding 
agents [8,9] . 
The interaction between the drugs and the nucleic acids can be studied when the physical 
properties of the ligand molecule change upon binding and are easily monitored. Spectroscopic 
techniques (UV-Visible absorption spectroscopy, fluorescence, circular dichroism) [10,11], equilibrium 
dialysis [12,13], surface plasmon resonance, [14,15] or calorimetric techniques [16,17] are commonly 
used to study ligand-DNA interactions. Electrospray ionization mass spectrometry has also shown its 
potential in the evaluation of DNA-ligand binding for more than a decade [18-26]. The study of the 
interaction of families of ligands with particular DNA structure like duplex and quadruplex structures 
can be made quickly. In these ESI-MS assays, the relative intensities of the free DNA and of the 
complexes is taken as a picture of the relative abundances of these species in solution [27], and this 
approach has proven valid when the ESI-MS data are compared with classical spectroscopic techniques 
[28-32].  
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The present paper reports for the first time the use of ESI-MS and ESI-MS/MS to study triplex 
DNA with noncovalently bound ligands. The ligand structures are shown in Scheme 1. The 
benzopyridoindole (BPI) ligands 1 and 2 are representatives of the benzo[e]pyridoindole (BePI, 1) and 
of the benzo[g]pyridoindole (BgPI, 2) families [33,34]. These molecules interact with duplex DNA 
[35], triplex DNA [34,36,37], and inhibit topoisomerases I and II [38]. Benzo[f]pyridoquinoxaline 
derivatives (BPQs, 3-5) were developed in order to target triplex DNA more specifically [39,40], while 
pyridoquinoxaline derivatives (PQ, 7) served to assess the role of the extra benzo ring. All these 
ligands are DNA intercalators [34,41,42]. Encouraged by the promising results obtained with BPQs, a 
new benzoquinoquinoxaline (BQQ, 6), was designed to optimize triplex interaction, synthesized, and 
successfully tested [43].  
Our goal here was to evaluate binding affinity and selectivity of these ligands for DNA duplexes 
of varying GC content, and for a triplex DNA, and to evaluate how tandem mass spectrometry 
(MS/MS) combined with molecular modeling can be used in order to obtain information on the ligand 
binding site. MS/MS data are interpreted using the transition state theory concepts [44-46]. The 
dissociation rate of the complex depends (1) on an enthalpy term which is the energy difference 
between the reactant (i.e. intact complex) and the transition state (the state at which dissociation 
becomes irreversible) (2) an entropy term which reflects the probability of the dissociation pathway 
and which depends on the mechanism and (3) on the internal energy. Consequently, when internal 
energy and dissociation pathways are the same, the dissociation rate should be related to the interaction 
energy in the complex. For small complexes, these interactions energies can be calculated by quantum 
chemical methods, but for large complexes like those DNA complexes studied here, molecular 
mechanics approaches are more practical. We will show here that, when the experimental MS/MS 
relative dissociation rates are compared to relative interaction energies calculated for different 
structural models, some structural interpretation can be made on the ligand binding mode. 
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MATERIALS AND METHODS 
Materials 
The self-complementary duplexes Dk33 (dCGTAAATTTACG)2, Dk66 
(dCGCGAATTCGCG)2, and Dk100 (dCGCGGGCCCGCG)2 were prepared in 100 mM aqueous 
NH4OAc.  All stock solutions were diluted to 50 µM at neutral pH. The triple helical DNA was 
prepared in 150 mM NH4OAc acidified with acetic acid (pH = 5.5), as previously described [47]. The 
triplex was formed from single strands dCCTTTTCTCTTTCC (T1), dGGAAAGAGAAAAGG (T2), 
which constitute a Watson-Crick duplex (T1•T2), and the strand dCCTTTCTCTTTTCC (T3) which is 
the antigene strand. Sequence T3 is the reverse of sequence T1. The oligonucleotides were purchased 
from Eurogentec (Seraing, Belgium) and used without further purification. 
The synthesis of the benzo[e]pyridoindole 1 (CA: 125974-68-7) and the benzo[f]pyridoindole 2 
(CA: 170890-29-6) was described in 1990 [33], the synthesis of the benzo[f]pyridoquinoxalines 3 (CA: 
165548-08-3), benzo[h]pyridoquinoxalines 4 (CA: 165548-10-7) and 5 (CA: 165548-11-8) and of the 
pyridoquinoxaline 7 (CA: 165548-02-7) was described in 1995 [39], and the synthesis of the 
benzo[f]quinoquinoxaline 6 (CA: 373595-26-7) was reported in 1998 [43]. The drug stock solutions 
were 100 or 200 µM in bi-distillated water. 
For ESI-MS, drug–duplex mixtures of 10 µM DNA and 15 µM drug were prepared in 150 mM 
NH4OAc and 15% methanol. The small proportion of methanol used (15%) does not disturb the 
particular DNA structures used in our assay as verified by CD (data not shown) and the high ionic 
strength used prevents the AT-rich duplex and the triplex from unfolding. The concentrations of the 
DNA stock solutions were checked no more than 3 days before the ESI-MS experiments by UV 
absorbance measurements. 
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Mass Spectrometry 
ESI-MS experiments were performed on a LCQ instrument (Finnigan LCQ ion trap instrument 
(ThermoFinnigan, SanJose, CA) equipped with its standard heated capillary electrospray source or a Q-
TOF Ultima Global (Micromass, now Waters, Manchester, UK) with its standard ESI source. On the 
LCQ, the needle voltage was set to -3.9 kV. The capillary was heated to 180 °C and the applied 
potential was -10 V. The skimmer was at ground potential and the tube lens offset was maintained at 
40V. On the Q-TOF, in negative ion mode the capillary voltage was set to −2.2 kV and the cone 
voltage to -35 V and the RF Lens1 to -70 V. The hexapole collision voltage of 10 V was used for full 
scan MS. The affinity of the drug for a given structure is deduced from the concentration of bound 
ligand per DNA molecule [27,30]. The concentration of bound ligand per DNA molecule is calculated 
from the relative intensities of the free DNA and of the complexes using the following equation (1): 
 
[Bound Ligand] = C0*(I(1:1)+2I(2:1)+3I(3:1))/(I(DNA)+I(1:1)+I(2:1)+I(3:1))    (1) 
 
where C0 is the starting DNA concentration (expressed in duplex or triplex concentration), 
I(DNA) is the relative intensity of the free DNA, and I(n:1) are relative intensities of the complexes (n 
drug molecules bound to one DNA structure). The concentrations of bound ligand were found 
independent on the instrument used. 
MS/MS experiments were all performed on the Q-TOF Ultima Global. This choice was done for two 
reasons. First, the mass range of the LCQ is limited to 2000 m/z and some triple helix fragments are 
observed m/z > 2000. Second, thanks to the higher-energy collision regime of the Q-TOF, direct 
noncovalent bond breaking is favored compared to rearrangement reactions giving neutral base losses 
[48]. The parent ion of interest was selected in the first quadrupole, and the hexapole collision voltage 
was varied. The argon pressure in the collision hexapole (3.0 × 10−5 mbar ± 5%) and the source 
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pressure (2.70 mbar) were carefully kept constant. Source block and desolvation temperatures were set 
to 70 ◦C and 100 ◦C, respectively. 
 
Molecular modeling 
Hyperchem 7.5 software (Hypercube, Inc.) has been used with AMBER99 force field. The 
starting duplex d(CGCGAATTCGCG)2 was the solution structure deposited in the Protein Data Bank 
with code 1GIP [49]. As these ligands are known to bind DNA by intercalation [34,41,42], three 
different intercalation sites on the duplex d(CGCGAATTCGCG)2 have been independently generated 
as follows. First, an increase of the space between two base pair by 3.4 Å was performed. Second, the 
twist angle of the helix (including one of the two base pair involved in the intercalation site) was 
decrease by 10 degree to compensate the change in the distance between the sugar-phosphate 
backbones. These parameters were chosen based on the structures of complexes between duplex DNA 
and intercalators found in PDB entries 2DES [50] and 1D10 [51]. Finally, local geometry optimization 
including the two base pairs and the backbone involved the intercalation site and the sugar-phosphate 
surrounding the site was performed to relax the system. Local geometry optimization was performed to 
relax the backbone surrounding the intercalation site. The intercalation sites were CG*CG, CG*AT and 
AT*AT. The global effect of the intercalation site on the duplex was the increase of the dimension of 
the grooves due to the decrease of the twisting angle of the two base pairs of the intercalating site. Each 
drug was manually docked in the intercalation site in different orientations as described in the text 
below, and energy minimized in the force field generated by the duplex until an energy gradient of 0.05 
kcal/(mol.Å) was reached (Polak-Riebiere conjugate gradient algorithm). The maximum gradient of the 
generated ligand-DNA was never higher than 0.3 kcal/(mol.Å) which is satisfactory (the DNA without 
drug has at a gradient of 0.2 kcal/(mol.Å) and indicated that no steric clash/problem is encountered. 
The same methodology as for the duplex was used to generate the intercalation sites and calculate the 
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interaction energies between the drugs and the triplex. The starting triplex model was generated using a 
smaller triple helical DNA (7 triplets) based on the NMR solution structure of a pyrimidine-purine-
pyrimidine DNA triplex (PDB entry 149D) [52]. Two intercalation sites between the base-triplet were 
generated: CGC-TAT and TAT-TAT. 
The interaction energy was calculated using the following equation (2): 
 
Eint = E(complex) – E(Ligand) – E(DNA)        (2) 
 
Where E(complex) is the complex energy, E(ligand) is the energy of the ligand with its geometry in 
the complex, and E(duplex) is the energy of the duplex with its geometry in the complex. 
 
RESULTS AND DISCUSSIONS 
ESI-MS determination of ligand selectivity.  
The sequence and structural selectivities of the seven compounds were first probed using ESI-
MS (Figure 1). Figure 1(a) shows the ESI-MS spectra obtained with the duplex 
d(CGCGGGCCCGCG)2 (DK100) or the triplex and ligand 6. <The 1:1 and 2:1 complex are detected. 
The amount of ligand 6 bound to the triplex under the experimental conditions is higher than to the 
duplex. We have previously shown a methodology to quantify the amount of bound ligand in DNA-
ligand mixtures using ESI-MS [27]. The methodology is based on the assumption that the relative 
intensities of the free DNA and of the complexes are proportional to the relative abundances in 
solution. This assumption has been shown valid in the case of double-stranded DNA complexed with 
minor groove binders [27,53]. The equilibrium binding constants for the 1:1 and 2:1 complexes with 6 
and the triplex measured by ESI-MS were K1 = 1.2 × 105 M-1, K2 = 3.9 × 104 M-1, respectively. In 
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comparison the values of the binding constants for the 1:1 and 2:1 complexes with 6 and the duplex 
were K1 = 3.2 × 104 M-1 and K2 = 3.7 × 104 M-1. This example shows the potentiality of ESI-MS to 
detect and quantify multiple drug-DNA stoichiometries present at equilibrium in solution.  
The calculated amounts of ligand bound to the different DNA structures are summarized in 
Figure 1(b). All drugs interact with the three DNA duplexes. Although intercalators usually show a 
preference for GC base pairs, this is not the case here, where even a small preference for AT-rich 
sequences is observed for some ligands, in agreement with footprinting studies [36]. The two 
benzopyridoindoles 1 and 2 have the highest duplex and triplex affinities compared to the other drugs.  
However, the BPI ligands (1 and 2) show no marked selectivity for the triple helix compared to duplex 
DNAs. Ligands 4, and 6 show substantial selectivity for the triplex while ligand 5 shows moderate 
selectivity. The aromatic rings of these three ligands share a common tetracyclic core. Ligands 4 and 5 
belong to the 8-amino-benzo[f]pyrido[3,4-b]quinoxaline family and are much more selective than 3 
(11-amino-benzo[f]pyrido[4,3-b]quinoxaline) where the benzene ring is linked to the other side on the 
quinoxaline. Ligand 7, which has the smallest heteroaromatic ring, has the lowest affinity for both 
DNA structures. Taken together, these observations suggest that the shape of the heteroaromatic ring 
system of these drugs therefore plays an important role in stacking interactions with the base triplets.  
ESI-MS/MS and molecular modeling on the (1:1) duplex-ligand complexes 
In the case of duplex-drug complexes, we have previously classified drugs in three categories, 
based on their dissociation pattern in tandem mass spectrometry experiments [54]. The first group 
includes drugs for which the complex dissociates mainly via the loss of a neutral drug. For the second 
group, the complex dissociates mainly via the loss of a negatively charged drug and for the third group 
via the separation of the strands (noted ss) which share the available charges and some drug molecule 
could stick on both strands. Here we have performed MS/MS experiments on the 1:1 (Drug-Dk66) 
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complex (Figure 2). All the complexes with each of the seven drugs dissociate mainly via the loss of a 
neutral drug. 
 
[DK66+Drug]5-  →  [Dk66]5-  +  Drug      (3) 
 
In the case where the dissociation mechanism is the same for a series of ligands, the CE50 
values are directly related to the activation energy of dissociation. This condition is fulfilled here as (1) 
the dissociation pathways are identical and (2) the parallel dissociation curves indicate similar 
activation entropies. Moreover, if the dissociation involves the loss of neutral ligand from the charged 
duplex, which is the case here, the activation energy is more likely to be proportional to the ligand 
binding energy [54].  
The dissociation pattern observed for all ligands is the same as for the drugs of the first group 
like cryptolepine, proflavine, daunomycin and doxorubicin [54]. Figure 2(a) clearly shows the larger 
collision energy necessary to dissociate the complexes with the BgPI 2 compared to the BPQ 3. At 14 
eV, the complex with 3 is nearly completely dissociated while only 15% of the complex with 2 is 
dissociated. Figure 2(b) represents the MS/MS dissociation curves obtained for all ligands.  












+       (4) 
 
The competitive dissociation of the duplex into the single strands (ss3- and ss2-) is only observed 
at collision energies > 18 eV, so this fragmentation channel does not perturb the ordering of CE50. The 
two BPI ligands 1 and 2 leave the duplex at higher energy than the quinoxaline derivatives (3-7). 
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Among the quinoxaline derivatives, 6 has the largest interaction energy with its binding site on the 
duplex (since higher collision energy is needed to dissociate the complex as compared to the other BPQ 
drugs). 
We performed molecular modeling to compare the interaction energies of a drug with different 
binding site sequences on duplex d(CGCGAATTCGCG)2 and to correlate the calculated interaction 
energies to the relative CE50 values obtained by MS/MS. Several groups have examined the molecular 
recognition and the dynamics of drug-DNA interactions using molecular modeling [55-57]. As the 
energetic parameters calculated by molecular modeling are related to the gas phase, the calculation 
using molecular modeling of the energetic of drug-DNA complexes allows a direct comparison with 
MS/MS experiments. 
The intercalation binding mode of these ligands was demonstrated previously [34,41,42]. Here 
two configurations were studied for each intercalation site: the alkyl chain of the drug can be oriented 
in two directions (Figure 3(a)). The central intercalation site is symmetric and only one orientation of 
the alkyl chain was studied for the CG*CG intercalation site (to prevent the aminoalkyl chain from 
going outside the duplex). The planar aromatic rings of the drugs were inserted into the duplex, with 
the alkyl chain laying in the minor groove allowing interaction between the side chain and the groove 
of the helix [34,41,42]. Small molecules generally interact via the DNA minor groove because it is 
narrower and more electronegative than the major groove, providing more favorable interactions with 
the ligand [58]. Only a small number of drugs like the bis-intercalator ditercalinium [59], or drugs that 
have large bulky groups [60], bind to duplex DNA through the major groove. Figure 3(b) shows the 
geometries of the generated complexes obtained between 2 and the duplex Dk66 after energy 
minimization. The values of the interaction energies obtained using Equation 2 are summarized in 
Table 1, together with the CE50 values obtained by MS/MS.  
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It is noteworthy that the interaction energies calculated for the intercalation site CG-CG, AT-
AT and CG-AT follow roughly the same ranking order as in the MS/MS experiments. Only the Eint 
obtained for the intercalation site CG-AT with the aminoalkyl tail oriented toward the GC-side ("up") 
does not follow the experimental trend. The absence of a significant dependence of interaction energies 
on the base sequence is in agreement with the absence of sequence selectivity observed for the duplex 
in full scan ESI-MS: figure 1(b) shows that the amount of bound ligand does not change according 
with the GC content of the duplex. In the population of complexes selected for MS/MS, the probability 
of the ligand being in GC-rich sites is therefore supposed to be proportional to the fraction of these 
sites.  
 
ESI-MS/MS and molecular modeling on the (1:1) triplex-ligand complexes 
Figure 4(a) shows the ESI-MS/MS spectra obtained at different collision energies for the BPQ 3 
(left) and the BgPI 2 (right). These two families of compounds show two different fragmentation 
patterns, summarized in Scheme 2. DNA complexes with quinoxaline derivatives dissociate principally 
via the loss of a neutral drug, while DNA-BPI complexes dissociate mainly via the loss of the antigene 
strand T3. Some ligand remains bound to the remaining duplex, but free duplex is detected as well. For 
ligands 3-7, loss of neutral ligand is almost complete before antigene loss starts, but for ligands 1-2 
antigene loss occurs at lower energies than loss of neutral ligand. There is therefore a competition 
between loss of neutral ligand and loss of antigene strand [T3]3-. Loss of neutral ligand occurs at lower 
collision voltage for ligands 3-7, while loss of antigene strand occurs at lower collision voltages for 
ligands 1-2. 
It must be pointed out that no drug is observed on the antigene strand, suggesting a stronger 
interaction with the Watson-Crick duplex part of the triplex. Figure 4(b) shows the dissociation curves 
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obtained for each drug. The percentage of intact complex is calculated using Equation (5), which is 




















+   (5) 
 
The two different fragmentation pathways do not necessarily imply that the binding modes are 
different. The breakdown curves of the duplex-ligand complexes also showed a large difference in 
dissociation threshold between ligands 1-2 and 3-7. The different dissociation pathways with the triplex 
can simply be due to the fact that the ligand loss threshold is well above the antigene loss threshold for 
ligands 1-2, and well below it for ligands 3-7. However, the fact that the breakdown curves are not 
strictly parallel is a stronger experimental argument indicating that different ligands could have 
different binding modes. Non-parallel curves indicate that the activation entropy of dissociation is 
different, suggesting that the dissociation mechanisms are different. This could in turn be due to a 
different binding mode. Note for example the crossing of the breakdown curves of ligands 1 and 2 in 
Figure 4(b), left. Among the pyridoquinoxaline drugs 3-7, ligand 6 needs the highest collision energy 
to be expelled, suggesting it is the best triplex binder of the series. 
For the molecular modeling, two intercalation sites were generated using the same procedure as 
for duplex: CGC-TAT and TAT-TAT. Four starting intercalation geometries were generated for each 
site: two with the drug docked with the alkyl chain in the major groove with the aminoalkyl chain 
going “up” (ie: amino group of the alkyl chain toward the 3’ end of the antigen strand) and “down” 
(aminoalkyl chain toward the 5’ end of the antigen strand) and two by intercalating the drug with the 
alkyl chain in the minor groove, and testing the two orientations of the chain (Figure 5(a)). A total of 
eight binding modes were therefore tested for each drug. We checked that the optimized conformations 
of the triplex with ligand 4 and 6 were stable in vacuo by running lengthy dynamics simulation (total of 
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5 ns) at the temperature of 300 K (data not shown). Although the helical conformation is slightly 
distorted (especially the 3' end of the antigene strand), hydrogen bonding in the base triplets involved 
in the ligand binding site is well conserved, and ligand binding mode remains the same as shown in 
Figure 5(c), thereby validating our modelling approach.  
The calculated interaction energies for the different binding sites are summarized in Table 2 
with the corresponding experimental voltage to observe 50 % dissociation (CE50) obtained by tandem 
mass spectrometry. The calculated interaction energies are the most favorable for the TAT-TAT 
binding site with the aromatic rings of the drugs inserted through the minor groove of the Watson-
Crick duplex and the aminoalkyl chain in the minor groove. For that binding site, the interaction 
energies follow the same ranking as the experimentally determined CE50 (Table 2). Figure 5(b) shows 
the structure of the complex with ligand 2 in that binding mode, and Figure 5(c) shows the 
superimposition of the ligand and the base triplet for ligands 4-7. The only exception is ligand 1, for 
which a significantly lowest energy site corresponds to the aminoalkyl chain in the major groove. In 
previous structure-affinity relationships and molecular modeling for BePI and BgPI derivatives, it was 
already suggested that the aminoalkyl chain was located in the minor groove of the duplex for BgPIs 
like 2 and in the major groove together with the antigene strand for BePIs like 1 [34]. Our calculations 
are also in line with this model and, coming back the MS/MS results, the fact that the breakdown 
curves of ligands 1 and 2 are not parallel can now be interpreted as an influence of the ligand binding 
mode on the activation entropy of dissociation. This illustrates that (1) a careful interpretation of the 
breakdown curves allows guessing that two of the ligands might have different binding modes, and (2) 
molecular modeling calculations, even at the modest level used here, could allow identifying the 
correct binding mode.  
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CONCLUSION 
The major conclusions of the present work are as follows. The benzopyridoindoles (1 and 2) have 
larger interaction energies than the pyridoquinoxalines (3-7). The nature of the heteroaromatic rings 
therefore plays a major role in the affinity of the ligand for the target. However, the benzopyridoindoles 
do not show any selectivity for the triplex compared to the duplex (see Figure 1). Molecular modeling 
indeed shows that BPI drugs interact preferentially with the Watson-Crick duplex and have small 
interaction with the antigen strand. Among the benzopyridoquinoxalines, the three most selective 
ligands (4, 5 and 6) all share the same heteroaromatic core, which best stacks on a base triplet (see 
Figure 5). Ligand 4 has stronger interaction with the base triplet than isomers 7 and 5. Our results 
consistently suggest that ligand 6 is the most promising lead for triplex-selective ligands. It has (i) the 
best triplex specificity, as shown by the ESI-MS screening (Figure 1), (ii) the highest interaction 
energy of all BPQs with the triplex, as shown by ESI-MS/MS (Figure 4 and Table 2), and (iii) the most 
favorable stacking configuration on a base triplet, as shown by molecular modeling (Figure 5(c)). This 
study demonstrates for the first time the use of ESI-MS and ESI-MS/MS to study drug-triplex 
interactions, and underlines the utility of molecular modeling for the interpretation of tandem mass 
spectrometry data in structural terms. 
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TABLE 1: Interaction energies calculated for each drug and intercalation site in the 
duplex (CGCGAATTCGCG)2.  
 
Drug CE50 (V) Eint (kcal/mol) 




1 16.6 -55.4 -57.2 -50.3 -42.7 
2 16.2 -55.5 -51.2 -55.9 -43.0 
6 11.1 -51.1 -51.2 -49.3 -43.2 
3 10.4 -53.5 -49.3 -42.7 -46.8 
4 9.6 -47.1 -46.3 -45.9 -41.0 
5 9.3 -47.5  -45.7 -45.6 -43.4 
7 9.2 -42.2 -41.9 -37.6 -40.8 
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TABLE 2: Interaction energies calculated for each drug and intercalation site in the 




































1 16.3 -33.5 -68.0 -53.4 -47.3 -46.1 -41.0 -66.4 -55.5 
2 17.0 -39.2 -44.0 -49.3 -44.7 -39.2 -48.2 -64.8 -62.9 
6 12.0 -45.6 -55.0 -59.5 -49.6 -46.5 -38.0 -64.4 -54.4 
3 10.5 -43.2 -52.1 -51.7 -48.2 -51.3 -38.8 -58.1 -47.8 
4 10.0 -43.5 -50.6 -50.2 -56.0 -47.5 -46.3 -55.5 -45.8 
5 9.3 -52.2 -46.8 -50.5 -47.2 -41.9 -46.5 -49.4 -48.7 
7 9.2 -33.7 -43.3 -53.8 -47.9 -38.6 -51.5 -51.9 -43.8 
 
Energy minimization to 0.05 kcal/(mol.A) using Polak-Ribiere gradient conjugate optimization algorithm. 
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Figure 1. ESI-MS screening of ligand-duplex and ligand-triplex binding. (a) Representative ESI-MS 
spectra with a duplex and triplex DNA: ESI-MS spectra of solution containing 10 µM DNA (duplex 
DK100 on the left and triplex on the right, see materials and methods for the sequences) and 15 µM 
of ligand 6. (b)  Relative ligand affinities for the different DNA structures: concentration of ligand 
bound (in µM bound out of 15 µM total ligand added to 10 µM DNA) to three duplexes and the 
triplex.  
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Figure 2: ESI-MS/MS experiments on [1:1]5- complexes with the duplex DK66. (a) Representative 
MS/MS spectra obtained with ligands 2 (left) and 3 (right), using collision energies of 10 and 14 eV. 
The argon pressure inside the hexapole collision cell was 3.0 10-5 mbar. (b) MS/MS breakdown 
curves of different intercalators drugs with the d(CGCGAATTCGCG)2 (Dk66) duplex. The % of 
intact complex was calculated using equation (4) for each collision energy. 
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Figure 3: Modeling of duplex-ligand binding sites. (a) Localization of the three intercalation sites 
used in the molecular modeling. A drug is represented in site 2, with two possible orientations (alkyl 
chain toward 5’ (down) or 3’ end (up) in respect to the first stand of the duplex). (b) Modeling of the 
complex between 2 and the duplex Dk66 in the intercalation site AT-AT, CG-AT with the aminoalkyl 
chain “down”, CG-AT with the chain “up” and CG-CG. The drug is shown in yellow. 
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Figure 4: ESI-MS/MS experiments on [1:1]5- complexes with the triplex. (a) Representative spectra 
obtained for quinoxaline drivatives (left, shown for ligand 3 at 10 and 12 eV collision energy) and 
BPIs (right, shown for ligand 2 at 16 and 20 eV collision energy). The argon pressure inside the 
hexapole collision cell was 3.0 × 10-5 mbar. (b) MS/MS breakdown curves of the different drugs with 
the triplex. The % of intact complex is calculated using Equation (5) for each collision energy. 
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Figure 5: Modeling of duplex-ligand binding sites. (a) Localization of the two intercalation sites used 
in the molecular modeling. A drug is represented for site 1. Two orientations of the drug are possible 
(alkyl chain toward 5’ or 3’ end in respect to the G-rich strand). The drug was docked either by the 
minor and the major groove of the helix. (b) Energy minimized structure of ligand 2 bound to the 
triplex (CTTTTCC*GAAAAGG-CTTTTCC), in site 2 (TAT-TAT) with the aminoalkyl chain 
“down”. The drug is colored in yellow, the Watson-Crick duplex in brown, and the antigene strand in 
green. (c) Zoom of the Energy-minimized models of 4, 5, 6, 7 intercalated in the TAT-TAT base 
triplets with the aminoalkyl chain “down”. The planar ring system of the ligands is shown stacked 
with the base triplet . Only the bottom triplet is shown for clarity. The drug is colored in mauve, the 
Watson-Crick duplex in brown and the antigen strand in green. 
